Autoimmune Diseases  >>  Avonex (recombinant IFN-β-1a)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
NCT00912860: Immunogenicity and Safety Study of Serum-Free Avonex

Completed
2
155
US
Interferon beta-1a, Avonex
Biogen
Multiple Sclerosis
12/04
01/05
NCT00324506: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Completed
2
43
US
Mycophenolate Mofetil (CellCept)
University of Texas Southwestern Medical Center, Aspreva Pharmaceuticals
Multiple Sclerosis
06/09
06/09
NCT00489489 / 2006-003134-14: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed
2
118
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for Teriflunomide), Interferon-β, Avonex®, Rebif®, Betaseron®
Sanofi
Multiple Sclerosis
06/09
06/09
NCT00811395 / 2007-003997-24: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed
2
182
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for teriflunomide), Interferon-β [IFN-β], Avonex®, Rebif®, Betaseron®, Glatiramer Acetate [GA], Copaxone®
Sanofi
Multiple Sclerosis
04/10
04/10
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12
SYNERGY, NCT01864148 / 2011-006262-40: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Checkmark SYNERGY trial in RRMS
Sep 2016 - Sep 2016: SYNERGY trial in RRMS
Hourglass Sep 2016 - Sep 2016 : Presentation from the SYNERGY study at ECTRIMS
Checkmark SYNERGY trial
Jun 2016 - Jun 2016: SYNERGY trial
More
Completed
2
419
US, Canada, Europe, RoW
BIIB033, anti-LINGO-1 mAb, Placebo, Avonex, interferon beta-1a
Biogen
Multiple Sclerosis
12/15
03/16
NCT01714089: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Withdrawn
2
0
US
RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
Revalesio Corporation
Relapsing Remitting Multiple Sclerosis
 
 

Download Options